Výsledky vyhledávání

Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function

Autor: van Leeuwen Fe, van Dijk M, Dalit Modan-Moses, Dorine Bresters, Claudia Spix, C.B. Lambalk, Jacqueline J. Loonen, Eva Clemens, A. Overbeek, Wassim Chemaitilly, van den Berg Mh, Gertjan L. Kaspers, Beerendonk Ccm, L. L. Robison, Sophie D. Fosså, van der Heiden-van der Loo M, Desiree Grabow, Peter Kaatsch, A.G. Uitterlinden, Melissa M. Hudson, van den Heuvel-Eibrink M, Russell J. Brooke, L. C. M. Kremer, van der Pal Hj, W.J.E. (Wim) Tissing, Falck Winther J, van der Kooi Alf, J. Kruseova, Uta Dirksen, Laven Jse, Claire Berger, Tomáš Kepák, Ronckers Cr, James M. Byrne, Pluijm Smf, Melanie Kaiser, de Vries Ach, Mvan Dulmen-den Broeder E, Linda Broer, Yutaka Yasui, Jesse H. Krijthe, Birgitta Versluys, O. Zolk, Riccardo Haupt

Publikováno v: Human Reproduction, 36(4), 1120-1133. Oxford University Press
van der Kooi, A L L F, van Dijk, M, Broer, L, van den Berg, M H, Laven, J S E, van Leeuwen, F E, Lambalk, C B, Overbeek, A, Loonen, J J, van der Pal, H J, Tissing, W J, Versluys, B, Bresters, D, Beerendonk, C C M, Ronckers, C R, van der Heiden-van der Loo, M, Kaspers, G L, de Vries, A C H, Robison, L L, Hudson, M M, Chemaitilly, W, Byrne, J, Berger, C, Clemens, E, Dirksen, U, Falck Winther, J, Fosså, S D, Grabow, D, Haupt, R, Kaiser, M, Kepak, T, Kruseova, J, Modan-Moses, D, Pluijm, S M F, Spix, C, Zolk, O, Kaatsch, P, Krijthe, J H, Kremer, L C, Yasui, Y, Brooke, R J, Uitterlinden, A G, van den Heuvel-Eibrink, M M & van Dulmen-den Broeder, E 2021, ' Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function ', Human Reproduction, vol. 36, no. 4, pp. 1120-1133 . https://doi.org/10.1093/humrep/deaa342
Human Reproduction (Oxford, England)
Human Reproduction, 36, 4, pp. 1120-1133
Human Reproduction, 36, 1120-1133
van der Kooi, A-L L F, van Dijk, M, Broer, L, van den Berg, M H, Laven, J S E, van Leeuwen, F E, Lambalk, C B, Overbeek, A, Loonen, J J, van der Pal, H J, Tissing, W J, Versluys, B, Bresters, D, Beerendonk, C C M, Ronckers, C C R, van der Heiden-van der Loo, M, Kaspers, G L, de Vries, A C H, Robison, L L, Hudson, M M, Chemaitilly, W, Byrne, J, Berger, C, Clemens, E, Dirksen, U, Falck Winther, J, Fosså, S D, Grabow, D, Haupt, R, Kaiser, M, Kepak, T, Kruseova, J, Modan-Moses, D, Pluijm, S M F, Spix, C, Zolk, O, Kaatsch, P, Krijthe, J H, Kremer, L C, Yasui, Y, Brooke, R J, Uitterlinden, A G, van den Heuvel-Eibrink, M M & van Dulmen-den Broeder, E 2021, ' Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function ', Human Reproduction, vol. 36, no. 4, pp. 1120-1133 . https://doi.org/10.1093/humrep/deaa342

STUDY QUESTION Do genetic variations in the DNA damage response pathway modify the adverse effect of alkylating agents on ovarian function in female childhood cancer survivors (CCS)? SUMMARY ANSWER Female CCS carrying a common BR serine/threonine kin

Vyhledávací nástroje:

Upřesnit hledání